Abstract
The uptake, processing and presentation of antigen by antigen presenting cells (APCs) such as macrophages and dendritic cells (DCs) plays a crucial role in the development of vaccines and immunotherapies against infectious diseases and cancer. Liposomes are nanoparticles composed of lipids/phospholipids that can be produced to exhibit properties mimicking those seen in pathogens; thus empowering liposomes with an inherent adjuvant activity and an ability to induce both humoral and cell-mediated immune responses. In addition to their adjuvanticity, liposomes can deliver to APCs large amounts of antigen, and immunostimulatory factors; they can readily incorporate “danger” or DC maturation signals, and be surface-modified to promote their active targeting to specific receptors on cells. Liposomes can also encapsulate or form complexes (lipoplexes) with plasmid DNA and small interfering RNA, enabling targeting of these nucleic acids directly to APCs as a DNA vaccine or to enhance immune responses. Since liposomes can be readily manipulated, are biocompatible and biodegradable, and are efficacious with a good record of safety, they clearly exhibit the attributes of potent arsenals for manipulating immune function and for developing more effective cancer vaccines and immunotherapies.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Aaltonen LM, Wahlström T, Rihkanen H, Vaheri A (1998) A novel method to culture laryngeal human papillomavirus-positive epithelial cells produces papilloma-type cytology on collagen rafts. Eur J Cancer 34:1111–1116
Abtin A, Eckhart L, Mildner M, Gruber F, Schroder JM, Tschachler E (2008) Flagellin is principal inducer of the anti-microbial peptide S100A7c in human epidermal keratinocytes exposed to Escherichia. coli. FASEB J 22:2168–2176
Akbari O, Panjwani N, Garcia S, Tascon R, Lowrie D, Stockinger B (1999) DNA vaccination: transfection and activation of dendritic cells as key events for immunity. J Exp Med 189:169–177
Akira S (2003) Mammalian Toll-like receptors. Curr Opin Immunol 15:5–11
Al-Deen FN, Ho J, Selomulya C, Ma C, Coppel R (2011) Superparamagnetic nanoparticles for effective delivery of malaria DNA vaccine. Langmuir 27:3703–3712
Alexander WS, Hilton DJ (2004) The role of suppressors of cytokine signalling (SOCS) proteins in the regulation of the immune response. Annu Rev Immunol 22:503–529
Aline F, Bout D, Amigorena S, Roingeard P, Dimier-Poisson I (2004) Toxoplasma gondii antigen-pulsed-dendritic cell-derived exosomes induce a protective immune response against T. gondii infection. Infect Immun 72:4127–4137
Allen TM, Hansen C, Martin F, Redemann C, Yau-Young A (1991) Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta 1066:29–36
Altin JG, Parish CR (2006) Liposomal vaccines – targeting the delivery of antigen. Methods 40:39–52
Altin JG, van Broekhoven CL, Parish CR (2004) Targeting dendritic cells with antigen-containing liposomes. Expert Opin Biol Ther 4:1735–1747
Alving CR (1990) Liposomes as carriers of antigen and adjuvant. J Immunol Methods 140:1–13
Ambrosch F, Wiedermann G, Jonas S, Althaus B, Finkle B, Gluck R, Herzog C (1997) Immunogenicity and protectivity of a new liposomal hepatitis A vaccine. Vaccine 15:1209–1213
Ardavin C, Amigorena S, Reis e Sousa C (2004) Dendritic cells: immunobiology and cancer immunotherapy. Immunity 20:17–23
Arie S (2011) Global HPV vaccination. BMJ 342:d1042
Bachmann MF, Jennings GT (2010) Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nature Rev Immunol 10:787–796
Bachmann MF, Beerli RR, Agnellini P, Wolint P, Schwarz K, Oxenius A (2006) Long-lived memory CD8+ T cells are programmed by prolonged antigen exposure and low levels of cellular activation. Eur J Immunol 36:842–854
Badiee A, Davies N, McDonald K, Radford K, Michiue H, Hart D, Kato M (2007) Enhanced delivery of immunoliposomes to human dendritic cells by targeting the multilectin receptor DEC-205. Vaccine 25:4757–4766
Baldridge JR, Crane RT (1999) Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines. Methods 19:103–107
Bartenschlager R (2006) Hepatitis C virus molecular clones: from cDNA to infectious virus particles in cell culture. Curr Opin Microbiol 9:416–422
Bege N, Renette T, Jansch M, Reul R, Merkel O, Petersen H, Curdy C, Müller RH, Kissel T (2011) Biodegradable poly(ethylene carbonate) nanoparticles as a promising drug delivery system with “stealth” potential. Macromol Biosci 11:897–904
Bei R, Scardino A (2010) TAA polyepitope DNA-based vaccines: a potential tool for cancer therapy. J Biomed Biotech Article ID 102758:1–12
Bodles-Brakhop AM, Draghia-Akli R (2008) DNA vaccination and gene therapy: optimization and delivery for cancer therapy. Expert Rev Vaccines 7:1085–1101
Bousso P, Robey E (2003) T cell priming by dendritic cells in intact lymph nodes. Nat Immunol 4:579–585
Buonaguro FM, Tornesello ML, Buonaguro L (2009) Virus-like particle vaccines and adjuvants: the HPV paradigm. Expert Rev Vaccines 8:1379–1398
Buonaguro L, Tagliamonte M, Tornesello ML, Buonaguro FM (2011) Developments in virus-like particle-based vaccines for infectious diseases and cancer. Expert Rev Vaccines 10:1569–1583
Butts C, Murray N, Maksymiuk A, Goss G, Marshall E, Soulieres D, Cormier Y, Ellis P, Price A, Sawhney R, Davis M, Mansi J, Smith C, Vergidis D, Ellis P, MacNeil M, Palmer M (2005) Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and stage IV non-small-cell lung cancer. J Clin Oncol 23:6674–6681
Butts C, Maksymiuk A, Goss G, Soulieres D, Marshall E, Cormier Y, Ellis PM, Price A, Sawhney R, Beier F, Falk M, Murray N (2011) Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial. J Cancer Res Clin Oncol 137:1337–1342
Caby MP, Lankar D, Vincendeau-Scherrer C, Raposo G, Bonnerot C (2005) Exosomal-like vesicles are present in human blood plasma. Int Immunol 17:879–887
Cannon G, Weissman D (2002) RNA based vaccines. DNA Cell Biol 21:953–961
Chan K, Lee DJ, Schubert A, Tang CM, Crain B, Schoenberger SP, Corr M (2001) The roles of MHC class II, CD40, and B7 costimulation in CTL induction by plasmid DNA. J Immunol 166:3061–3066
Chen J, Ni G, Liu XS (2011) Papillomavirus virus like particle-based therapeutic vaccine against human papillomavirus infection related diseases: immunological problems and future directions. Cell Immunol 269:5–9
Cheng WW, Allen TM (2010) The use of single chain Fv as targeting agents for immunoliposomes: an update on immunoliposomal drugs for cancer treatment. Expert Opin Drug Deliv 7:461–478
Cheng P, Corzo CA, Luetteke N, Yu B, Nagaraj S, Bui MM, Ortiz M, Nachen W, Song C, Vogl T, Roth J, Gabrilovich DI (2008) Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer. J Exp Med 205:2235–2249
Chhabra A, Chakraborty NG, Mukherji B (2008) Silencing of endogenous IL-10 in human dendritic cells leads to generation of improved CTL response against human melanoma epitope MART-127–35. Clin Immunol 126:251–259
Christ D, Famm K, Winter G (2007) Repertoires of aggregation-resistant human antibody domains. Protein Eng Des Sel 20:413–416
Christensen D, Agger EM, Andreasen LV, Kirby D, Andersen P, Perrie Y (2009) Liposome-based cationic adjuvant formulations (CAF): past, present, and future. J Liposome Res 19:2–11
Christensen D, Korsholm KS, Andersen P, Agger EM (2011) Cationic liposomes as vaccine adjuvants. Expert Rev Vaccines 10:513–521
Corrales-Rodriguez L, Blais N, Soulières D (2011) Emepepimut-S for non-small cell lung cancer. Expert Opin Biol Ther 11:1091–1097
Cox JC, Sjölander A, Barr IG (1998) ISCOMs and other saponin based adjuvants. Adv Drug Deliv Rev 32:247–271
Cruz LJ, Rueda F, Cordobilla B, Simon L, Hosta L, Albericio F, Domingo JC (2010) Targeting nanosystems to human DCs via Fc receptor as an effective strategy to deliver antigen for immunotherapy. Mol Pharm 8:104–116
Curtis KK, Connolly MK, Northfelt DW (2008) Live, attenuated varicella zoster vaccination of an immunocompromised patient. J Gen Intern Med 23:648–649
Daudel D, Weidinger G, Spreng S (2007) Use of attenuated bacteria as delivery vectors for DNA vaccines. Expert Rev Vaccines 6:97–110
Davis ID, Chen W, Jackson H, Parente P, Shackleton M, Hopkins W, Chen Q, Dimopoulos N, Luke T, Murphy R, Scott AM, Maraskovsky E, McArthur G, MacGregor D, Sturrock S, Tai TY, Green S, Cuthbertson A, Maher D, Miloradovic L, Mitchell SV, Ritter G, Jungbluth AA, Chen YT, Gnjatic S, Hoffman EW, Old LJ, Cebon JS (2005) Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci USA 102:10697–10702
de Gassart A, Geminard C, Fevrier B, Raposo G, Vidal M (2003) Lipid raft-associated protein sorting in exosomes. Blood 102:4336–4344
de Lima MC, Simoes S, Pires P, Gaspar R, Slepushkin V, Duzgunes N (1999) Gene delivery mediated by cationic liposomes: from biophysical aspects to enhancement of transfection. Mol Membr Biol 16:103–109
Demento SL, Siefert AL, Bandyopadhyay A, Sharp FA, Fahmy TM (2011) Pathogen-associated molecular patterns on biomaterials: a paradigm for engineering new vaccines. Trends Biotechnol 29:294–306
Di D, Teoh WY, Gooding JI, Selomulya C, Amal R (2010) Functionization strategies for protease immobilization on magnetic nanoparticles. Adv Funct Mater 20:1767–1777
Di Lorenzo G, Buonerba C, Kantoff PW (2011) Immunotherapy for the treatment of prostate cancer. Nat Rev Clin Oncol 8:551–561
Drake CG (2010) Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol 10:580–593
Eisenbarth SC (2008) Use and limitations of alum-based models of allergy. Clin Exp Allergy 38:1572–1575
Eisenbarth SC, Colegio OR, O’Connor W, Sutterwala FS, Flavell RA (2008) Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453:1122–1126
Elamanchili P, Diwan M, Cao M, Samuel J (2004) Characterization of poly(D, L-lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells. Vaccine 22:2406–2412
El-Aneed A (2004) An overview of current delivery systems in cancer gene therapy. J Control Release 94:1–14
Eliasson DG, Helgeby A, Schon K, Nygren C, El-Bakkouri K, Fiers W, Saelens X, Lövgren KB, Nyström I, Lycke NY (2011) A novel non-toxic combined CTA1-DD and ISCOMS adjuvant vector for effective mucosal immunization against influenza virus. Vaccine 29:3951–3961
Erikçi E, Gursel M, Gürsel I (2011) Differential immune activation following encapsulation of immunostimulatory CpG oligodeoxynucleotide in nanoliposomes. Biomaterials 32:1715–1723
Espuelas S, Thumann C, Heurtault B, Schuber F, Frisch B (2008) Influence of ligand valency on the targeting of immature human dendritic cells by mannosylated liposomes. Bioconjug Chem 19:2385–2393
Faham A, Altin JG (2010) Antigen-containing liposomes engrafted with flagellin-related peptides are effective vaccines that can induce potent antitumor immunity and immunotherapeutic effect. J Immunol 185:1744–1754
Faham A, Altin JG (2011) Ag-bearing liposomes engrafted with peptides that interact with CD11c/CD18 induce potent Ag-specific and antitumor immunity. Int J Cancer 129:1391–1403
Faham A, Bennett D, Altin JG (2009) Liposomal Ag engrafted with peptides of sequence derived from HMGB1 induce potent Ag-specific and anti-tumour immunity. Vaccine 27:5846–5854
Faham A, Herringson T, Parish C, Suhrbier A, Khromykh AA, Altin JG (2011) PDNA-lipoplexes engrafted with flagellin-related peptide induce potent immunity and anti-tumour effects. Vaccine 29:6911–6919
Fehr T, Skrastina D, Pumpens P, Zinkernagel RM (1998) T cell-independent type I antibody response against B cell epitopes expressed repetitively on recombinant virus particles. Proc Natl Acad Sci USA 95:9477–9481
Ferlazzo C, Tsang ML, Moretta L, Melioi G, Steinman RM, Munz C (2002) Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med 195:343–351
Feuillet V, Medjane S, Mondor I, Demaria O, Pagni PP, Galan JE, Flavell RA, Alexopoulou L (2006) Involvement of toll-like receptor 5 in the recognition of flagellated bacteria. Proc Natl Acad Sci USA 103:12487–12492
Fifis T, Gamvrellis A, Crimeen-Irwin B, Pietersz GA, Li J, Mottram PL, McKenzie IF, Plebanski M (2004a) Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J Immunol 173:3148–3154
Fifis T, Mottram P, Bogdanoska V, Hanley J, Plebanski M (2004b) Short peptide sequences containing MHC class I and/or class II epitopes linked to nano-beads induce strong immunity and inhibition of growth of antigen-specific tumour challenge in mice. Vaccine 23:258–266
Figdor CG, de Vries IJM, Lesterhuis WJ, Melief CJM (2004) Dendritic cell immunotherapy: mapping the way. Nat Med 10:475–480
Flavell RA, Sanjabi S, Wrzesinski SH, Licona-Limon P (2010) The polarization of immune cells in the tumour environment by TGF&UF062. Nat Rev Immunol 10:554–567
Foged C, Arigita C, Sundblad A, Jiskoot W, Storm G, Frokjaer S (2004) Interaction of dendritic cells with antigen-containing liposomes: effect of bilayer composition. Vaccine 22:1903–1913
Fong L, Engleman EG (2000) Dendritic cells in cancer immunotherapy. Annu Rev Immunol 18:245–273
Fooks AR (2000) Development of oral vaccines for human use. Curr Opin Mol Ther 2:80–86
Foster N, Hirst BH (2005) Exploiting receptor biology for oral vaccination with biodegradable particulates. Adv Drug Deliv Rev 57:431–450
Frazer IH, Levin MJ (2011) Paradigm shifting vaccines: prophylactic vaccines against latent varicella-zoster virus infection and against HPV-associated cancer. Curr Opin Virol 1:268–279
Freeman GJ, Casasnovas JM, Umetsu DT, DeKruyff RH (2010) TIM genes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity. Immunol Rev 235:172–189
GabizonA PD (1992) The role of surface charge and hydrophilic groups on liposome clearance in vivo. Biochim Biophys Acta 1103:94–100
Geijtenbeek TBH, Gringhuis SI (2009) Signalling through C-type lectin receptors: shaping the immune responses. Nat Rev Immunol 9:465–479
Ghosh P, Han G, De M, Kim CK, Rotello VM (2008) Gold nanoparticles in delivery applications. Adv Drug Deliv Rev 60:1307–1315
Gordon S (2002) Pattern recognition receptors. Cell 111:927–930
Gram GJ, Karlsson I, Agger EM, Andersen P, Fomsgaard A (2009) A novel liposome-based adjuvant CAF01 for induction of CD8+ cytotoxic T-lymphocytes (CTL) to HIV-1 minimal CTL peptides in HLA-A*0201 transgenic mice. PLoS One 4:e6950
Greenwood DLV, Dynon K, Kalkanidis M, Xiang S, Plebanski M, Scheerlinck J-P Y (2008) Vaccination against foot-and-mouth disease virus using peptides conjugated to nano-beads. Vaccine 26:2706–2713
Gregoriadis G (1994) The immunological adjuvant and vaccine carrier properties of liposomes. J Drug Target 2:351–356
Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S (2002) Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 20:621–667
Gursel I, Gursel M, Ishii KJ, Klinman DM (2001) Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides. J Immunol 167:3324–3328
Hamdy S, Molavi O, Ma Z, Haddadi A, Alshamsan A, Gobti Z, Elhasi S, Samuel J, Lavasanifar A (2008) Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity. Vaccine 26:5046–5057
Hamdy S, Haddadi A, Hung RW, Lavasanifar A (2011) Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations. Adv Drug Deliv Rev 63:943–955
Hamzah J, Altin JG, Herringson T, Parish CR, Hammerling GJ, O’Donoghue H, Ganns R (2009) Targeted liposomal delivery of TLR9 ligands activates spontaneous antitumor immunity in an autochthonous cancer model. J Immunol 183:1091–1098
Hanley C, Thurber A, Hanna C, Punnoose A, Zhang J, Wingett DG (2009) The influences of cell type and ZnO nanoparticle size on immune cell cytotoxicity and cytokine induction. Nanoscale Res Lett 4:1409–1420
Hansen CB, Kao GY, Moase EH, Zalipsky S, Allen TM (1995) Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures. Biochim Biophys Acta 1239:133–144
Hansen J, Lindenstrøm T, Lindberg-Levin J, Aagaard C, Andersen P, Agger EM (2011) CAF05: cationic liposomes that incorporate synthetic cord factor and poly(I:C) induce CTL immunity and reduce tumor burden in mice. Cancer Immunol Immunother [Epub ahead of print] PMID: 22095092
Harper DM (2009) Currently approved prophylactic HPV vaccines. Expert Rev Vaccines 8:1663–1679
Hashimoto M, Avada T, Kinjvo I, Hiwatashi K, Yoshida H, Okada Y, Kobayashi T, Yoshimura A (2009) Silencing SOCS1 in macrophages suppresses tumour development by antitumor inflammation. Cancer Sci 100:730–736
Heath WR, Carbone FR (2009) Dendritic cell subsets in primary and secondary T cell responses at body surfaces. Nat Immunol 10:1237–1244
Heath WR, Belz GT, Behrens GMN, Smith CM, Forehan SP, Parish IA, Davey GM, Wilson NS, Carbone FR, Villandangos JA (2004) Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol Rev 199:9–26
Heffernan MJ, Zaharoff DA, Fallon JK, Schlom J, Greiner JW (2011) In vivo efficacy of a chitosan/IL-12 adjuvant system for protein-based vaccines. Biomaterials 321:926–932
Henriksen-Lacey M, Korsholm KS, Andersen P, Perrie Y, Christensen D (2011) Liposomal vaccine delivery systems. Expert Opin Drug Deliv 8:505–519
Herringson TP, Altin JG (2009) Convenient targeting of stealth siRNA-lipoplexes to cells with chelator lipid-anchored molecules. J Control Release 39:229–238
Herringson TP, Patlolla RR, Altin JG (2009) Targeting of plasmid DNA-lipoplexes to cells with molecules anchored via a metal chelator lipid. J Gene Med 11:1048–1063
Hiwatashi K, Yoshida H, Okada Y et al (2009) Silencing SOCS1 in macrophages suppresses tumour development by antitumor inflammation. Cancer Sci 100:730–736
Ho J, Al-Deen FM, Al-Abboodi A, Selomulya C, Xiang SD, Plebanski M, Forde GM (2011) N, N’-Carbonyldiimidazole-mediated functionalization of superparamagnetic nanoparticles as vaccine carrier. Colloids Surf B Biointerfaces 83:83–90
Hong B, Ren W, Song XT, Evel-Kabier K, Chen SY, Huang XF (2009) Human suppressor of cytokine signalling 1 controls immunostimulatory activity of monocyte-derived dendritic cells. Cancer Res 69:8076–8084
Hou W-S, Van Parijs L (2004) A Bcl-2-dependent molecular timer regulates the lifespan and immunogenicity of dendritic cells. Nat Immunol 5:583–589
Immordino ML, Dosio F, Catlel L (2006) Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine 1:297–315
Jackson H, Dimopoulos N, Mifsud NA, Tai TY, Chen Q, Svobodova S, Browning J, Luescher I, Stockert L, Old LJ, Davis ID, Cebon J, Chen W (2006) Striking immunodominance hierarchy of naturally occurring CD8+ and CD4+ T cell responses to tumor antigen NY-ESO-1. J Immunol 176:5908–5917
Jain S, O’Hagan DT, Singh M (2011) The long-term potential of biodegradable poly(lactide-co-glycolide) microparticles as the next-generation vaccine adjuvant. Expert Rev Vaccines 10:1731–1742
Janes KA, Calvo P, Alonso MJ (2001) Polysaccharide colloidal particles as delivery systems for macromolecules. Adv Drug Del Rev 47:83–97
Jensen-Jarolim E, Singer J (2011) Cancer vaccines inducing antibody production: more pros than cons. Expert Rev Vaccines 10:1281–1289
Jespers L, Schon O, Famm K, Winter G (2004) Aggregation-resistant domain antibodies selected on phage by heat denaturation. Nat Biotechnol 22:1161–1165
Jiang W, Swiggard WJ, Heufler C, Peng M, Steinman RM, Nussenzweig MC (1995) The receptor DEC-205 expressed by dendritic cells and thymic epithelium cells is involved in antigen processing. Nature 375:151–155
Jin MS, Lee J-O (2008) Structures of the Toll-like receptor family and its ligand complexes. Immunity 29:182–191
Johansen P, Storni T, Rettig L, Qiu Z, Der-Sarkissian A, Smith KA, Manolova V, Lang KS, Senti G, Mullhaupt B, Gerlach T, Speck RF, Bot A, Kundig TM (2008) Antigen kinetics determines immune reactivity. Proc Natl Acad Sci USA 105:5189–5194
Kaisho T, Akira S (2002) Toll-like receptors as adjuvant receptors. Biochim Biophys Acta 1589:1–13
Kamath AT, Rochat AF, Christensen D, Agger EM, Andersen P, Lambert PH, Siegrist CA (2009) A liposome-based mycobacterial vaccine induces potent adult and neonatal multifunctional T cells through the exquisite targeting of dendritic cells. PLoS One 4:e5771
Karkarda M, Weir GM, Quinton T, Feutes-Ortega A, Mansour M (2010) A liposome-based platform, Vaccimax, and its modified water-free platform DepoVax enhance efficacy of in vivo nucleic acid delivery. Vaccine 28:6176–6182
Kennedy R, Celis E (2008) Multiple roles for CD4+ T cells in anti-tumor immune responses. Immunol Rev 222:129–144
Kersten G, Hirschberg H (2004) Antigen delivery systems. Expert Rev Vaccines 3:453–462
Khatri K, Goyal AK, Gupta PN, Mishra N, Vyas SP (2008) Plasmid DNA loaded chitosan nanoparticles for nasal mucosal immunization against hepatitis B. Int J Pharm 354:235–241
Kim TW, Lee J-H, He L, Boyd DA, Hardwick JM, Hung CF, Wu TC (2005) Modification of professional APCs with small interfering RNA in vivo to enhance cancer vaccine potency. Cancer Res 65:309–316
Kobayashi T, Yoshimura A (2005) Keeping DCs awake by putting SOCS1 to sleep. Trends Immunol 26:177–179
Kool M, Pétrilli V, De Smedt T, Rolaz A, Hammad H, van Nimwegen M, Bergen IM, Castillo R, Lambrecht BN, Tschopp J (2008) Cutting edge: alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome. J Immunol 181:3755–3759
Korsholm KS, Agger EM, Foged C, Christensen D, Dietrich J, Andersen CS, Geisler C, Andersen P (2007) The adjuvant mechanism of cationic dimethyldioctadecylammonium liposomes. Immunology 121:216–226
Kotton CN (2008) Vaccination and immunization against travel-related diseases in immunocompromised hosts. Expert Rev Vaccines 7:663–672
Krishnan SGD (2008) Archaeosome adjuvants: immunological capabilities and mechanism (s) of action. Vaccine 26:2043–2055
Krishnan SS, Patel GB, Sprott GD (2000) Archaeosomes induce long-term CD8+ cytotoxic T cell response to entrapped soluble protein by the exogenous cytosolic pathway, in the absence of CD4+ T cell help. J Immunol 165:5177–5185
Krishnan L, Sad S, Patel GB, Sprott GD (2003) Archaeosomes induce enhanced cytotoxic T lymphocyte responses to entrapped soluble protein in the absence of interleukin 12 and protect against tumor challenge. Cancer Res 63:2526–2534
Kumar D, Kirimanjeswara G, Metzger DW (2011) Intranasal administration of an inactivated Yersinia pestis vaccine with interleukin-12 generates protective immunity against pneumonic plague. Clin Vaccine Immunol 18:1925–1935
Kumari A, Yadav SK, Yadav SC (2010) Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces 75:1–18
Lahoud MH, Ahmet F, Kitsoulis S, Wan SS, Vremec D, Lee CN, Phipson B, Shi W, Smyth GK, Lew AM, Kato Y, Mueller SN, Davey GM, Heath WR, Shortman K, Caminschi I (2011) Targeting antigen to mouse dendritic cells via Clec9A induces potent CD4 T cell responses biased toward a follicular helper phenotype. J Immunol 187:842–850
Laing P, Bacon A, McCormack B, Bregoriadis G, Frisch B, Schber F (2006) The ‘co-delivery’ approach to liposomal vaccines: application to the development of influenza-A and hepatitis-B vaccine candidates. J Liposome Res 16:229–235
Lasic DD, Papahadjopoulos D (1995) Liposomes revisited. Science 267:1275–1276
Lasic DD, Martin FJ, Gabizon A, Huang SK, Papahadjopoulos D (1991) Sterically stabilized liposomes: a hypothesis on the molecular origin of the extended circulation times. Biochim Biophys Acta 1070:187–192
Lee K-D, Hong K, Papahadjopoulos D (1992) Recognition of liposomes by cells: in vitro binding and endocytosis mediated by specific lipid headgroups and surface charge density. Biochim Biophys Acta 1103:185–197
Lenarczyk A, Le TT, Drane D, Malliaros J, Pearse M, Hamilton R, Cox J, Luft T, Gardner J, Suhbrier A (2004) ISCOM based vaccines for cancer immunotherapy. Vaccine 22:963–974
Lesterhuis WJ, Haanen JB, Punt CJ (2011) Cancer immunotherapy–revisited. Nat Rev Drug Discov 10:591–600
Li WM, Bally MB, Schutze-Redelmeier MP (2001) Enhanced immune response to T-independent antigen by using CpG oligodeoxynucleotides encapsulated in liposomes. Vaccine 20:148–57
Li Y, Hu Y, Jin Y, Zang G, Wong J, Sun LQ, Wang M (2011) Prophylactic, therapeutic and immune enhancement effect of liposome-encapsulated PolyICLC on highly pathogenic H5N1 influenza infection. J Gene Med 13:60–72
Lin YL, Liang YC, Chiang BL (2007) Placental growth factor down-regulates Th1 T immune response by modulating the function of dendritic cells. J Leukoc Biol 82:1473–1480
Liu MA (2011) DNA vaccines: an historical perspective and view to the future. Immunol Rev 239:62–84
Liu G, Ng H, Akasaki Y, Yuan X, Ehtesham M, Yin D, Black KL, Yu JS (2004) Small interference RNA modulation of IL-10 in human monocyte-derived DCs enhances the Th1 response. Eur J Immunol 171:691–696
Lovgren Bengtsson K, Morein B, Osterhaus AD (2011) ISCOM technology-based Matrix MTM adjuvant: success in future vaccines relies on formulation. Expert Rev Vaccines 10:401–403
Lu Y, Kawakami S, Yamashita F, Hashida M (2007) Development of an antigen-presenting cell-targeted DNA vaccine against melanoma by mannosylated liposomes. Biomaterials 28:3255–3262
Lutsiak ME, Robinson DR, Coester C, Kwon GS, Samuel J (2002) Analysis of poly(D, L-lactic-co-glycolic acid) nanosphere uptake by human dendritic cells and macrophages in vitro. Pharm Res 19:1480–1487
Ma Y, Zhuang Y, Xie X, Wang C, Wang F, Zhou D, Zeng J, Cai I (2011) The role of surface charge density in cationic liposome-promoted dendritic cell maturation and vaccine-induced immune responses. Nanoscale 3:2307–2314
Maeda T, Balakrishnan K, Mehdi SQ (1983) A simple and rapid method for the preparation of plasma membranes. Biochim Biophys Acta 731:115–120
Manjappa AS, Chaudhari KR, Venkataraju MP, Dantuluri P, Nanda B, Sidda C, Sawant KK, Ramachandra Murphy RS (2011) Antibody derivatization and conjugation strategies: application in preparation of stealth immunoliposome to target chemotherapeutics to tumor. J Control Release 150:2–22
Manley CA, Leibman NF, Wolchok JD, Riviere IC, Barlido S, Craft DM, Bergman PJ (2011) Xenogeneic murine tyrosinase DNA vaccine for malignant melanoma of the digit of dogs. J Vet Intern Med 25:94–99
Mansouri S, Lavigne P, Corsi K, Benderdour M, Beaumont E, Fernandes JC (2004) Chitosan-DNA nanoparticles as non-viral vectors in gene therapy: strategies to improve transfection efficacy. Eur J Pharm Biopharm 57:1–8
Marigo I, Dolcetti L, Serafini P, Zanovello P, Bronte V (2008) Tumour-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev 222:162–179
Marrack P, McKee AS, Munks MW (2009) Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol 9:287–293
Martinon F, Burns K, Tschopp J (2002) The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 10:417–426
Marutama K, Kennel SJ, Huang L (1990) Lipid composition is important for highly efficient target binding and retention of immunoliposomes. Proc Natl Acad Sci USA 87:5744–5748
McManus MT, Sharp PA (2002) Gene silencing in mammals by small interfering RNAs. Nat Rev Genet 3:737–747
Miller MJ, Hejazi AS, Wei SH, Cahalan MD, Parker I (2004) T cell repertoire scanning is promoted by dynamic dendritic cell behaviour and random T cell motility in the lymph node. Proc Natl Acad Sci USA 101:998–1003
Minigo G, Scholzen A, Tang CK, Hanley JC, Kalkanidis M, Pietersz GA, Apostolopoulos V, Plebanski M (2007) Poly-L-lysine-coated nanoparticles: a potent delivery system to enhance DNA vaccine efficacy. Vaccine 25:1316–1327
Miyanishi M, Tada K, Koike M, Uchiyama Y, Kitamura T, Nagata S (2007) Identification of Tim4 as a phosphatidylserine receptor. Nature 450:435–439
Mockey M, Bourseau E, Chandrashekhar V, Chaudhuri S, Lafosse E, Le Cam E, Quesniaux VFJ, Ryffel B, Pichon C, Midoux P (2007) MRNA-based cancer vaccine: prevention of B16 melanoma progression and metastasis by systemic injection of MART1 mRNA histidylated lipopolyplexes mRNA-based cancer vaccine. Cancer Gene Ther 14:802–814
Montecalvo A, Shufesky WJ, Stolz DB, Sullivan MG, Wang Z, Divito SJ, Papworth GD, Watkins SC, Robbins PD, Larrengina AT, Morelli AE (2008) Exosomes as a short-range mechanism to spread alloantigen between dendritic cells during T cell allorecognition. J Immunol 180:3081–3090
Montomoli E, Piccirella S, Khadang B, mennitto E, Camerini R, de Rosa A (2011) Current adjuvants and new perspectives in vaccine formulation. Expert Rev Vaccines 10:1053–1061
Moser M, Murphy KM (2000) Dendritic cell regulation of TH1-TH2 development. Nat Immunol 1:199–205
Mottram PL, Leong D, Crimeen-Irwin B, Gloster S, Xiang SD, Meanger J, Ghildyal R, Vardaxis N, Plebanski M (2007) Type 1 and 2 immunity following vaccination is influenced by nanoparticle size: formulation of a model vaccine for respiratory syncytial virus. Mol Pharm 4:73–84
Mui B, Raney SG, Semple SC, Hope MJ (2001) Immune stimulation by a CpG-containing oligodeoxynucleotide is enhanced when encapsulated and delivered in lipid particles. J Pharmacol Exp Ther 298:1185–1192
Nakanishi T, Kunisawa J, Hayashi A, Tsutsumi Y, Kubo K, Nakagawa S, Nakanashi M, Tanaka K, Mayumi T (1999) Positively charged liposome functions as an efficient immunoadjuvant in inducing cell-mediated immune response to soluble proteins. J Control Release 61:233–240
Naylor CJ, Jones RC (1994) Demonstration of a virulent subpopulation in a prototype live attenuated turkey rhinotracheitis vaccine. Vaccine 12:1225–1230
Nchinda G, Zschornig O, Uberla K (2003) Increased non-viral gene transfer levels in mice by concentration of cationic lipid DNA complexes formed under optimized conditions. J Gene Med 5:712–722
Nelson K, Janssen JM, Troy SB, Maldonado Y (2011) Intradermal fractional dose inactivated polio vaccine: a review of the literature. Vaccine 30:121–125
Newman KD, Elamanchili P, Kwon GS, Samuel J (2002) Uptake of poly(D, L-lactic-coglycolic acid) microspheres by antigen-presenting cells in vivo. J Biomed Mater Res 60:480–486
Nicholaou T, Chen W, Davis ID, Jackson HM, Dimopoulos N, Barrow C, Browning J, Macgregor D, Williams D, Hopkins W, Maraskovsky E, Venhaus R, Pan L, Hoffman EW, Old LJ, Cebon J (2011) Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™. Cancer Immunol Immunother 60:1625–1637
Oszlánczi G, Papp A, Szabó A, Nagymajteny L, Sapi A, Konya Z, Paulik E, Vezer T (2011) Nervous system effects in rats on subacute exposure by lead-containing nanoparticles via the airways. Inhal Toxicol 23:173–181
Oyewumi MO, Kumar A, Cui Z (2010) Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune response. Expert Rev Vaccines 9:1095–1107
Panda AK (2011) Induction of anti-tumor immunity and T-cell responses using nanodelivery systems engrafting TLR-5 ligand. Expert Rev Vaccines 10:155–157
Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthay K, Huang SK, Lee K-D, Woodle MC, Lasic DD, Redemann C, Martin FJ (1991) Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA 88:11460–11464
Park D, Hochreiter-Hufford A, Ravichandran KS (2009) The phosphatidylserine receptor TIM-4 does not mediate direct signaling. Curr Biol 19:346–351
Patel CW (2005) Archaeosome immunostimulatory vaccine delivery system. Curr Drug Deliv 2:407–421
Patel GB, Chen W (2010) Archaeal lipid mucosal vaccine adjuvant and delivery system. Expert Rev Vaccines 9:431–440
Patel ZH, Ponce A, Chen W (2007) Mucosal and systemic immune responses by intranasal immunization using archaeal lipid-adjuvanted vaccines. Vaccine 25:8622–8636
Patel PA, Zhou H, Chen W (2008) Safety of intranasally administered archaeal lipid mucosal vaccine adjuvant and delivery (AMVAD) vaccine in mice. Int J Toxicol 27:329–339
Pelkmans L (2005) Viruses as probes for systems analysis of cellular signalling, cytoskeleton reorganization and endocytosis. Curr Opin Microbiol 8:331–337
Peng S, Kim TW, Lee JH, Yang M, He L, Hung CF, Wu TC (2005) Vaccination with dendritic cells transfected with BAK and BAX siRNA enhances antigen-specific immune responses by prolonging dendritic cell life. Hum Gene Ther 16:584–593
Perche F, Gosset D, Mével M, Ml M, Yaouanc JJ, Pichon C, Benvegnu T, Jaffres PA, Midoux P (2011) Selective gene delivery in dendritic cells with mannosylated and histidylated lipopolyplexes. J Drug Target 19:315–325
Peres J (2011) For cancers caused by HPV, two vaccines were just the beginning. J Natl Cancer Inst 103:360–362
Piechocki MP, Ho Y-S, Pilon S, Wei W-Z (2003) Human ErbB-2 (Her-2) transgenic mice: a model system for testing Her-2 based vaccines. J Immunol 171:5787–5794
Pinzon-Charry A, Maxwell T, Lopez AJ (2005) Dendritic cell dysfunction in cancer: A mechanism for immunosuppression. Immunol Cell Biol 83:451–461
Pirollo KF, Zon G, Rait A, Zhou Q, Yu W, Hogrefe R, Chang EH (2006) Tumour-targeting nanoimmunoliposome complex for short interfering RNA delivery. Hum Gene Ther 17:117–124
Prasad S, Cody V, Saucier-Sawyer JK, Saltzman WM, Sasaki CT, Edelson RL, Birchall MA, Hanlon DJ (2011) Polymer nanoparticles containing tumor lysates as antigen delivery vehicles for dendritic cell-based antitumor immunotherapy. Nanomedicine 7:1–10
Pulendran B, Tang H, Manicassamy S (2010) Programming dendritic cells to induce TH2 and tolerogenic responses. Nat Immunol 11:647–655
Radkevich-Brown O, Jacob J, Kershaw M, Wei W-Z (2009) Genetic regulation of the response to Her-2 DNA vaccination in human Her-2 Tg mice. Cancer Res 69:212–218
Reed SG, Berthalet S, Coler RN, Friede M (2008) New horizons in adjuvants for vaccine development. Trends Immunol 30:23–32
Rice J, Ottensmeier CH, Stevenson FK (2008) DNA vaccines: precision tools for activating effective immunity against cancer. Nat Rev Cancer 8:108–120
Rice-Ficht AC, Arenas-Gamboa AM, Kahl-McDonagh MM, Ficht TA (2010) Polymeric particles in vaccine delivery. Curr Opin Microbiol 13:106–112
Rieux AD, Fievez V, Garinot M, Schneider Y-J, Preat V (2006) Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J Control Release 116:1–27
Rodriguez LL, Gay CG (2011) Development of vaccines toward the global control and eradication of foot-and-mouth disease. Expert Rev Vaccines 10:377–387
Roldão A, Mellado MCM, Castilho LR, Carrondo MJT, Alves PM (2010) Virus-like particles in vaccine development. Expert Rev Vaccines 9:1149–1176
Roman F, Clément F, Dewe W, Walravens K, Maes C, Willekens J, De Boever F, Hanon E, Leroux-Roels G (2011) Effect on cellular and humoral immune responses of the AS03 adjuvant system in an A/H1N1/2009 influenza virus vaccine administered to adults during two randomized controlled trials. Clin Vaccine Immunol 18:835–843
Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10:909–915
Sallusto F, Geginat J, Lanzavecchia A (2004) Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 22:745–763
Sangha R, Butts C (2007) L-BLP25: a peptide vaccine strategy in non-small cell lung cancer. Clin Cancer Res 13:s4652–s4654
Sangha R, North S (2007) L-BLP25: a MUC1-targeted peptide vaccine therapy in prostate cancer. Expert Opin Biol Ther 7:1723–1730
Sangha R, Price J, Butts CA (2010) Adjuvant therapy in non-small cell lung cancer: current and future directions. Oncologist 15:862–872
Schijns VE, Degen WG (2007) Vaccine immunopotentiators of the future. Clin Pharmacol Ther 82:750–755
Schliehe C, Schliehe C, Thiry M, Tromsdorf UI, Hentschel J, Weller H, Groettrup M (2011) Microencapsulation of inorganic nanocrystals into PLGA microsphere vaccines enables their intracellular localization in dendritic cells by electron and fluorescence microscopy. J Control Release 151:278–285
Schwendener RA, Ludewig B, Cerny A, Engler O (2010) Liposome-based vaccines. Methods Mol Biol 605:163–175
Serre K, Giraudo L, Leserman L, Machy P (2003) Liposomes targeted to Fc receptors for antigen presentation by dendritic cells in vitro and in vivo. Methods Enzymol 373:100–118
Sharma A, Sharma US (1997) Liposomes in drug delivery: progress and limitations. Int J Pharm 154:123–140
Sharma S, Srivastava MK, Harris-White M, Lee JM, Dubinett S (2011) MUC1 peptide vaccine mediated antitumor activity in non-small cell lung cancer. Expert Opin Biol Ther 11:987–990
Sharp FA, Ruane D, Claass B, Creagh E, Harris J, Malyala P, Singh M, O’Hagan DT, Petrilli V, Tschopp J, O’Neill LA, Lavelle EC (2009) Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc Natl Acad Sci USA 106:870–875
Shedlock DJ, Weiner DB (2000) DNA vaccination: antigen presentation and the induction of immunity. J Leukoc Biol 68:793–806
Shen L, Evel-Kabler K, Strube R, Chen SY (2004) Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity. Nat Biotech 22(12):1546–1553
Shen L, Evel K, Strube R, Chen S-Y (2005) Critical regulation of Ag presentation by SOCS1 in dendritic cells and implications for vaccine development. Proc Amer Assoc Cancer Res Immunology 7:Dendritic cell-based immunotherapy. Abstract# 4235
Shortman K, Heath WR (2010) The CD8+ dendritic cell subset. Immunol Rev 234:18–31
Shortman K, Liu Y-J (2002) Mouse and human dendritic cell subtypes. Nat Rev Immunol 2:151–161
Shortman K, Naik SH (2007) Steady-state and inflammatory dendritic-cell development. Nat Rev Immunol 7:19–30
Shrivastava S, Lole KS, Tripathy AS, Shaligram US, Arankalle VA (2009) Development of candidate combination vaccine for hepatitis E and hepatitis B: A liposome encapsulation approach. Vaccine 27:6582–6588
Signori E, Iurescia S, Massi E, Fioretti D, Chiarella P, De Robertis M, Rinaldi M, Tonon G, Fazio VM (2010) DNA vaccination strategies for anti-tumour effective gene therapy protocols. Cancer Immunol Immunother 59:1583–1591
Skene CD, Sutton P (2006) Saponin-adjuvanted particulate vaccines for clinical use. Methods 40:53–59
Skene CD, Doidge C, Sutton P (2008) Evaluation of ISCOMATRIX and ISCOM vaccines for immunisation against Helicobacter pylori. Vaccine 26:3880–3884
Skwarczynski M, Toth I (2011) Peptide-based subunit nanovaccines. Curr Drug Deliv 8:282–289
Song E, Lee S-K, Wang J, Ince N, Ouyang N, Min J, Chen J, Shankar P, Lieberman J (2003) RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med 9:347–351
Song E, Zhu P, Lee S-K, Chowdhury D, Kussman S, Dykxhoorn DM, Feng Y, Palliser D, Weiner DB, Shankar P, Marasco WA, Lieberman J (2005) Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotech 23:709–717
Sorensen DR, Leirdal M, Sioud M (2003) Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J Mol Biol 327:761–766
Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M, Elbashir S, Geick A, Hadwiger P, Harborth J, John M, Kesavan V, Lavine G, Pandey RK, Racie T, Rajeev KG, Röhl I, Toudjarska I, Wang G, Wuschko S, Bumcrot D, Koteliansky V, Limmer S, Manoharan M, Vornlocher HP (2004) Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432:173–178
Stagg J, Sharkey J, Pommey S, Pommey S, Young R, Takeda K, Yagita H, Johnstone RW, Smyth MJ (2008) Antibodies targeted to TRAIL receptor-2 and Erb-2 synergise and induce an antitumor response. Proc Nat Acad Sci 105:16254–16259
Steers NJ, Peachman KK, McClain S, Alving CR, Rao M (2009) Liposome-encapsulated HIV-1 Gag p24 containing lipid A induces effector CD4+ T-cells, memory CD8+ T-cells, and pro-inflammatory cytokines. Vaccine 27:6939–6949
Steinhagen F, Kinjo T, Bode C, Klinman DM (2011) TLR-based immune adjuvants. Vaccine 29:3341–3355
Steinman RM (2008) Dendritic cells in vivo: a key target for a new vaccine science. Immunity 29:319–324
Steinman RM, Banchereau J (2007) Taking dendritic cells into medicine. Nature 449:419–426
Steinman RM, Hemmi H (2006) Dendritic cells: translating innate to adaptive immunity. Curr Top Microbiol Immunol 311:17–58
Steinman RM, Idoyaga J (2010) Features of the dendritic cell lineage. Immunol Rev 234:5–17
Stobiecka M, Hepel M (2011) Double-shell gold nanoparticle-based DNA-carriers with poly-L-lysine binding surface. Biomaterials 32:3312–21
Suhrbier A (2002) Polytope vaccines for the codelivery of multiple CD8 T-cell epitopes. Expert Rev Vaccines 1:207–213
Sun J-Y, Krouse RS, Forman SJ, Senitzer D, Sniecinski I, Chatterjee S, Wong KK Jr (2002) Immunogenicity of a p210BCR-ABL fusion domain candidate DNA vaccine targeted to dendritic cells by a recombinant adeno-associated virus vector in vitro. Cancer Res 62:3175–3183
Tacken PJ, Torensma R, Figdor CG (2006) Targeting antigens to dendritic cells in vivo. Immunobiology 211:599–608
Tacken PJ, de Vries IJM, Torensma R, Fidgor CG (2007) Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol 7:790–802
Taneichi M, Ishida H, Kajino K, Ogasawara K, Tanaka Y, Kasai M, Mori M, Nishidia M, Yamamura H, Mizuguchi J, Uchida T (2006) Antigen chemically coupled to the surface of liposomes are cross-presented to CD8+ T cells and induce potent antitumor immunity. J Immunol 177:2324–2330
Tang C-K, Apostolopoulos V (2008) Strategies used for MUC1 immunotherapy: preclinical studies. Expert Rev Vaccines 7:951–962
Tang CK, Sheng K-C, Pouniotis D, Esparon S, Son H-Y, Kim C-W, Pietersz GA, Apostolopoulos V (2008) Oxidised and reduced mannan mediated MUC1 DNA immunization induce effective anti-tumor responses. Vaccine 26:3827–3834
Tefit JN, Serra V (2011) Outlining novel cellular adjuvant products for therapeutic vaccines against cancer. Expert Rev Vaccines 10:1207–1220
Thery C, Zitvogel L, Amigorena S (2002) Exosomes: composition, biogenesis and function. Nat Rev Immunol 2:569–579
Thery C, Ostrowski M, Segura E (2009) Membrane vesicles as conveyers of immune responses. Nat Rev Immunol 9:581–593
Thomann JS, Heurtault B, Weidner S, Braye M, Beyrath J, Fournel S, Schuber F, Frisch B (2011) Antitumor activity of liposomal ErbB2/HER2 epitope peptide-based vaccine constructs incorporating TLR agonists and mannose receptor targeting. Biomaterials 32:4574–4583
Torchilin VP (2005) Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 4:145–160
Torchilin VP (2008) Antibody-modified liposomes for cancer chemotherapy. Expert Opin Drug Deliv 5:1003–1025
Tritto E, Mosca F, De Gregorio E (2009) Mechanism of action of licensed vaccine adjuvants. Vaccine 27:3331–3334
U’Ren L, Kedl R, Dow S (2006) Vaccination with liposome-DNA complexes elicits enhanced anti-tumor immunity. Cancer Gene Ther 13:1033–1044
Ulrich AS (2002) Biophysical aspects of using liposomes as delivery vehicles. Biosci Rep 22:129–150
van Broekhoven CL, Altin JG (2002) A novel approach for modifying tumor cell-derived plasma membrane vesicles to contain encapsulated IL-2 and engrafted costimulatory molecules for use in tumor immunotherapy. Int J Cancer 98:63–72
van Broekhoven CL, Altin JG (2005) The novel chelator lipid 3(nitrilotriacetic acid)-ditetradecylamine (NTA(3)-DTDA) promotes stable binding of His-tagged proteins to liposomal membranes: potent anti-tumor responses induced by simultaneously targeting antigen, cytokine and costimulatory signals to T cells. Biochim Biophys Acta 1716:104–116
van Broekhoven CL, Parish CR, Demangel C, Britton WJ, Altin JG (2004) Targeting dendritic cells with antigen-containing liposomes: a highly effective procedure for inducing anti-tumour immunity and for tumour immunotherapy. Cancer Res 64:4357–4365
van der Aar AM, Sylva-Steenland RM, Bos JD, Kapsenberg ML, de Jong EC, Teuissen MB (2007) Loss of TLR2, TLR4 and TLR5 on Langerhan cells abolishes bacterial recognition. J Immunol 178:1986–1990
Vangasseri DP, Cui Z, Chen W, Hokey DA, Falo LD, Huang L (2006) Immunostimulation of dendritic cells by cationic liposomes. Mol Membr Biol 23:385–395
Villadangos JA, Schnorrer P (2007) Intrinsic and cooperative antigen-presenting functions of dendritic-cell subsets in vivo. Nat Rev Immunol 7:543–555
Vyas SP, Goyal AK, Khatri K (2010) Mannosylated liposomes for targeted vaccines delivery. Methods Mol Biol 605:177–188
Wang C, Ge Q, Ting D, Nguyen D, Shen HR, Chen J, Eisen HN, Heller J, Langer R, Putnam D (2004a) Molecularly engineered poly(ortho ester) microspheres for enhanced delivery of DNA vaccines. Nat Mater 3:190–196
Wang Z, Troilo P, Wang X, Griffiths TG, Pacchione SJ, Barnum AB, Harper LB, Pauley CJ, Niu Z, Denisova L, Follmer TT, Rizzuto G, Ciliberto G, Fattori E, Monica NL, Manam S, Ledwith BJ (2004b) Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation. Gene Ther 11:711–721
Wen ZS, Xu YL, Zou XT, Xu ZR (2011) Chitosan nanoparticles act as an adjuvant to promote both Th1 and Th2 immune responses induced by ovalbumin in mice. Mar Drugs 9:1038–1055
White KL, Rades T, Furneaux RH, Tyler PC, Hook S (2006a) Mannosylated liposomes as antigen delivery vehicles for targeting to dendritic cells. J Pharm Pharmacol 58:729–737
White K, Rades T, Kearns P, Toth I, Hook S (2006b) Immunogenicity of liposomes containing lipid core peptides and adjuvant Quil a. Pharm Res 23:1473–1481
Wichmann HE (2007) Diesel exhaust particles. Inhal Toxicol 19:241–244
Wong K, Valdez PA, Tan C, Yeh S, Hongo JA, Ouyang W (2010) Phosphatidylserine receptor Tim-4 is essential for the maintenance of the homeostatic state of resident peritoneal macrophages. Proc Natl Acad Sci USA 107:8712–8717
Xiang SD, Scalzo-Inguanti K, Minigo G, Park A, Hardy CL, Plebanski M (2008) Promising particle-based vaccines in cancer therapy. Expert Rev Vaccines 7:1103–1119
Xiang SD, Selomulya C, Ho J, Apostolopoulos V, Plebanski M (2010) Delivery of DNA vaccines: an overview on the use of biodegradable polymeric and magnetic nanoparticles. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2:205–218
Yanagisawa R, Takano H, Inoue KI, Koike E, Sadakane K, Ichinose T (2010) Size effects of polystyrene nanoparticles on atopic dermatitis-like skin lesions in NC/NGA mice. Int J Immunopathol Pharmacol 23:131–141
Yang L, Carbone DP (2004) Tumor host immune interactions and dendritic cell dysfunction. Adv Cancer Res 92:13–27
Yang P, Duan Y, Wang C, Xing L, Gao X, Tang C, Luo D, Zhao Z, Jia W, Peng D, Liu X, Wang X (2011) Immunogenicity and protective efficacy of a live attenuated vaccine against the 2009 pandemic A H1N1 in mice and ferrets. Vaccine 29:698–705
You Z, Huang X, Hester J, Toh HC, Chen SY (2001) Targeting dendritic cells to enhance DNA vaccine potency. Cancer Res 61:3704–3711
Yukihiko A, Hiroyuki S, Seishi T (1995) Interferon-γ inductive effect of liposomes as an immunoadjuvant. Vaccine 13:1809–1814
Zaharoff DA, Rogers CJ, Hance KW, Schlom J, Greiner JW (2007) Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination. Vaccine 25:2085–2094
Zaharoff DA, Hoffman BS, Hooper HB, Benjamin CJ Jr, Khurana KK, Hance KW, Rogers CJ, Pinto PA, Schlom J, Greiner JW (2009) Intra vesical immunotherapy of superficial bladder cancer with chitosan/interleukin-12. Cancer Res 69:6192–6199
Zaks K, Jordan M, Guth A, Sellins K, Kedl R, Izzo A, Bosio C, Dow S (2006) Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes. J Immunol 176:7335–7345
Zelenay S, Elias F, Flo J (2003) Immunostimulatory effects of plasmid DNA and synthetic oligodeoxynucleotides. Eur J Immunol 33:1382–1392
Zhang Y, Boado RJ, Pardridge WM (2003) Marked enhancement in gene expression by targeting the human insulin receptor. J Gene Med 5:157–163
Zhang S, Zhang H, Shi H, Yu X, Kong W, Li W (2008) Induction of immune response and anti-tumor activities in mice with DNA vaccine encoding human mucin 1 variable-number tandem repeats. Hum Immunol 69:250–258
Zhang Z, Tongchusak S, Mizukami Y, Kang YJ, Ioji T, Touma M, Reinhold B, Keskin DB, Reinherz EL, Sasada T (2011) Induction of anti-tumor cytotoxic T cell responses through PLGA-nanoparticle mediated antigen delivery. Biomaterials 32:3666–3678
Zheng X, Vladau C, Zhang X, Suzuki M, Ichim TE, Zhang ZX, Li M, Carrier E, Garcia B, Jevnikar AM, Min WP (2009) A novel in vivo siRNA delivery system specifically targeting dendritic cells and silencing CD40 genes for immunomodulation. Blood 113:2646–2654
Zhou H, Zhang D, Wang Y, Dai M, Zhang L, Liu W, Liu D, Tan H, Huang Z (2006) Induction of CML28-specific cytotoxic T cell responses using co-transfected dendritic cells with CML28 DNA vaccine and SOCS1 small interfering RNA expression vector. Biochem Biophys Res Commun 347:200–207
Zou W (2006) Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 6:295–307
Acknowledgements
This work was supported by Project Grants from the NHMRC of Australia (Number 316949) and from the ACT Cancer Society (App1028722). The author is grateful for the input of collaborators including Prof. Christopher R. Parish (JCSMR, ANU) and research students now Drs Thomas P. Herringson and Abdus Faham, for their contribution to the original research that led to the author’s work described in this review.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Altin, J.G. (2012). Liposomes and Other Nanoparticles as Cancer Vaccines and Immunotherapeutics. In: Baschieri, S. (eds) Innovation in Vaccinology. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-4543-8_7
Download citation
DOI: https://doi.org/10.1007/978-94-007-4543-8_7
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-4542-1
Online ISBN: 978-94-007-4543-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)